Working… Menu

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients (LIVERAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01022476
Recruitment Status : Completed
First Posted : December 1, 2009
Last Update Posted : July 18, 2013
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
ANRS, Emerging Infectious Diseases

Tracking Information
First Submitted Date  ICMJE November 26, 2009
First Posted Date  ICMJE December 1, 2009
Last Update Posted Date July 18, 2013
Study Start Date  ICMJE May 2010
Actual Primary Completion Date May 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 30, 2009)
Pharmacokinetic parameters of raltegravir in patients with severe liver dysfunction and after a liver transplantation when combined to immunosuppressive therapy. Pharmacokinetic parameters of immunosuppressive drugs with or without raltegravir [ Time Frame: at month 1 for period 1 and day 7-month 1 for period 2 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 30, 2009)
  • To assess the maintenance of the virological efficacy on HIV of raltegravir combined with two fully active molecules among NRTI (or NRTI + enfuvirtide). Follow-up over a 3-months period before and after transplantation [ Time Frame: from day 0 to month 3 for period 1 and period 2 ]
  • To assess the safety of raltegravir before transplantation in patients with impaired liver function, and after transplantation in combination with immunosuppressive treatment [ Time Frame: from day 0 to month 3 for period 1 and period 2 ]
  • To describe the clinical outcome of patients (such as the onset of opportunistic infections, relapse of HCV infection, morphological and metabolic disorders outcomes) [ Time Frame: from day 0 to month 3 for period 1 and period 2 ]
  • To describe the changes in liver function (evaluation of liver function during treatment) before and after liver transplantation [ Time Frame: from day 0 to month 3 for period 1 and period 2 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
Official Title  ICMJE A Pilot Study of Pharmacokinetics, Tolerance and Efficacy of Raltegravir Combined to Two Fully Active Molecules Among Nucleosi(ti)de Analogs and Enfuvirtide Before and After Liver Transplant in HIV Infected Patients With End Stage Liver Disease (ANRS 148 LIVERAL)
Brief Summary This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with immunosuppressive therapy in liver transplant recipients.
Detailed Description HIV infected patients with stable plasma HIV-RNA below 50 copies per mL and severe liver dysfunction will be switched from their antiretroviral regimen to a combination of raltegravir (one 400 mg pill twice daily) and two fully active molecules among nucleosi(ti)de analogs and enfuvirtide for a first period of at least 3 months and a second period of at least 3 months after liver transplantation, if need be, when a steady state of the anticalcineurin will be reached. Pharmacokinetic parameters of raltegravir will be calculated during severe liver dysfunction period and after liver transplantation. Pharmacokinetic parameters of cyclosporine (or tacrolimus if contra indication to cyclosporine) will be compared when administrated alone or combined with raltegravir. Patients will be followed up according to standard of care. This study will be divided in two distinct periods (1 and 2) lasting 3 months each. Period 1 will start from the inclusion in the study and will generally include the switch to raltegravir. Period 2 will start from liver transplantation.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • HIV Infection
  • Liver Failure
  • Evidence of Liver Transplantation
Intervention  ICMJE Drug: Raltegravir potassium
one pill of raltegravir 400 mg twice a day
Study Arms  ICMJE Experimental: Raltegravir potassium
raltegravir 400 mg twice a day
Intervention: Drug: Raltegravir potassium
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 17, 2013)
Original Estimated Enrollment  ICMJE
 (submitted: November 30, 2009)
Actual Study Completion Date  ICMJE May 2013
Actual Primary Completion Date May 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥ 18
  • Documented HIV-1 infection, hepatitis B or C co-infection is allowed
  • Plasma viral load at screening visit below 50 copies per mL for at least 6 months
  • Patient with severe liver failure (Meld Score ≥ 15 and/or refractory ascites and/or haemorrhage of digestive tract and/or hepatic encephalopathy) for taking part into period 1
  • Patient eligible for the liver transplant waiting list or immediate post transplantation for taking part into period 2
  • Abstinence from alcohol intake for at least 6 months (WHO norm)
  • Withdrawal from intravenous drug use for at least 6 months (methadone substitution is permitted)
  • No ongoing class C opportunistic infection (1993 CDC classification)
  • Patient whose clinical and immunovirological condition allows triple therapy with raltegravir + 2 NRTI or raltegravir + NRTI + enfuvirtide
  • Patient whose HIV population, according to cumulative genotypes carried out on viral RNA together with treatment history (if available and interpreted as per the ANRS-AC11 algorithm version no.19) does not present a profile of mutations associated with resistance to raltegravir and is sensitive to at least two fully active* agents selected among nucleoside/nucleotide reverse transcriptase analogs NRTI (abacavir, lamivudine, emtricitabine, tenofovir) or enfuvirtide

    *An ARV agent is considered to be fully active if the cumulative genotypes do not show any mutation associated with resistance or any mutation associated with "possible resistance"

  • Patient not having experienced viral escape during treatment combining 3TC, FTC or raltegravir
  • Patient registered with or covered by a social security scheme
  • For women of child-bearing potential, use of a barrier contraceptive method during sexual intercourse and negative pregnancy test (plasma ß-HCG ) at screening visit
  • Informed consent form signed at screening visit at the latest

Exclusion Criteria:

  • More than two virological failures during antiretroviral treatment
  • Currently receiving treatment with an agent in development (apart from an authorization for temporary use)
  • Plasma viral load at screening visit ≥ 50 copies per mL during at least the last 6 months
  • Pregnant women, or women liable to become pregnant, breast-feeding women, no contraception, or refusal to use contraception
  • All conditions (including but not limited to alcohol intake and drug use) liable to compromise, in the investigator's opinion, the safety of treatment and/or the patient's compliance with the protocol
  • Patient not having any effective options for NRTI +/- enfuvirtide (defined in the inclusion criteria)
  • Ongoing treatment with interferon-alpha or ribavirin for hepatitis C
  • Concomitant medication including one or more agents liable to induce UGT1A1 and reduce raltegravir concentrations:

    • anti-infective agents: rifampicin/rifampin
    • psychotropic/antiepileptic agents: phenytoin, phenobarbital, carbamazepine
    • steroidal anti-inflammatory drug: dexamethasone
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01022476
Other Study ID Numbers  ICMJE 2009-014616-36
ANRS 148 LIVERAL ( Other Identifier: ANRS )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party ANRS, Emerging Infectious Diseases
Study Sponsor  ICMJE ANRS, Emerging Infectious Diseases
Collaborators  ICMJE Merck Sharp & Dohme Corp.
Investigators  ICMJE
Principal Investigator: Elina TEICHER, MD Hôpital de Bicêtre - LE KREMLIN-BICETRE - FRANCE
PRS Account ANRS, Emerging Infectious Diseases
Verification Date July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP